We have located links that may give you full text access.
Comparative Study
English Abstract
Journal Article
Randomized Controlled Trial
[Clinical randomized comparative trial of ProMACE-CytaBOM regimen and CHOP regimen in treating non-Hodgkin's lymphoma].
BACKGROUND & OBJECTIVE: CHOP regimen is the routine modality for moderately or highly malignant non-Hodgkin's lymphoma (NHL). Previous reports show that ProMACE-CytaBOM regimen could elevate complete response rate and survival rate of patients with moderately or highly malignant NHL. This study was to compare efficacies and safeties of ProMACE-CytaBOM and CHOP regimens in treating this disease, to indicate the standard treatment for it.
METHODS: A total of 146 patients with moderately or highly malignant NHL, verified by pathology or histology, were randomized into trial group (73 patients treated with ProMACE-CytaBOM regimen) and control group (73 patients treated with CHOP regimen). Survival rate was analyzed by Kaplan-Meier method. Chi-square test was performed between groups.
RESULTS: The complete response rate, partial response rate, and response rate was significantly higher in ProMACE-CytaBOM group than in CHOP group (39.7% vs. 31.5%, 38.4% vs. 28.8%, and 78.1% vs. 60.3%, respectively, P < 0.05). The 1-, 3-, and 5-year survival rates were significantly higher in ProMACE-CytaBOM group than in CHOP group (89.3% vs. 82.1%, 76.2% vs. 51.4%, and 45.7% vs. 32.3%, respectively, P < 0.05). The major side effects, appeared with no differences (P > 0.05) in incidences between 2 groups, were leukopenia, thrombocytopenia, and nausea. Each group had 1 case of treatment-related death.
CONCLUSIONS: The results show higher efficacy of ProMACE-CytaBOM regimen over CHOP regimen. ProMACE-CytaBOM regimen may prolong survival time of patients with moderately or highly malignant NHL.
METHODS: A total of 146 patients with moderately or highly malignant NHL, verified by pathology or histology, were randomized into trial group (73 patients treated with ProMACE-CytaBOM regimen) and control group (73 patients treated with CHOP regimen). Survival rate was analyzed by Kaplan-Meier method. Chi-square test was performed between groups.
RESULTS: The complete response rate, partial response rate, and response rate was significantly higher in ProMACE-CytaBOM group than in CHOP group (39.7% vs. 31.5%, 38.4% vs. 28.8%, and 78.1% vs. 60.3%, respectively, P < 0.05). The 1-, 3-, and 5-year survival rates were significantly higher in ProMACE-CytaBOM group than in CHOP group (89.3% vs. 82.1%, 76.2% vs. 51.4%, and 45.7% vs. 32.3%, respectively, P < 0.05). The major side effects, appeared with no differences (P > 0.05) in incidences between 2 groups, were leukopenia, thrombocytopenia, and nausea. Each group had 1 case of treatment-related death.
CONCLUSIONS: The results show higher efficacy of ProMACE-CytaBOM regimen over CHOP regimen. ProMACE-CytaBOM regimen may prolong survival time of patients with moderately or highly malignant NHL.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app